EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada

Katarzyna J Jerzak, Sandeep Sehdev, Jean-François Boileau, Christine Brezden-Masley iD, Nadia Califaretti iD, Scott Edwards, Jenn Gordon, Jan-Willem Henning iD, Nathalie LeVasseur iD, Cindy Railton

Current Oncology · 2025

DOI: 10.3390/curroncol32080444 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Current Oncology, 2025. Verfasst von Katarzyna J Jerzak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly (Canada), Karamjeet Singh, PhD and Andrea Brumwell, PhD of MEDUCOM Health Inc., Eli Lilly Canada Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinase (CDK)4/6 inhibitors have become a key component of adjuvant treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer who are at high risk of recurrence. The addition of abemaciclib and ribociclib to standard endocrine therapy has demonstrated clinically meaningful improvements in invasive disease-free survival, supported by the monarchE and NATALEE trials, respectively. With expansion of patient eligibility for CDK4/6 inhibitors, multidisciplinary coordination among medical oncologists, surgeons, nurses, pharmacists, and other health care providers is critical to optimizing patient identification, monitoring, and management of adverse events. This expert guidance document provides practical recommendations for implementing adjuvant CDK4/6 inhibitor therapy in routine clinical practice, incorporating insights from multiple specialties and with patient advocacy representation. Key considerations include patient selection based on clinical trial data, treatment duration, dosing schedules, adverse event profiles, monitoring requirements, drug–drug interactions, and patient-specific factors such as tolerability, cost, and quality of life. This guidance aims to support Canadian clinicians in effectively integrating CDK4/6 inhibitors into clinical practice, ensuring optimal patient outcomes through a multidisciplinary and patient-centric approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsFemaleHumansCanadaChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, Progesterone

Stichwörter der Autor:innen

CDK4/6 inhibitorsHR+, HER2− early breast canceradjuvant therapymultidisciplinary carepractical recommendations

Substanzen

CDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanProtein Kinase InhibitorsReceptors, EstrogenReceptors, Progesterone

Autor:innen und Institutionen

  • Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
  • Division of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada.
  • Department of Surgery, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
  • Department of Medical Oncology, Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
  • Grand River Regional Cancer Centre, Kitchener, ON N2G 1G3, Canada.
  • Dr. H. Bliss Murphy Cancer Centre, St. John's, NL A1B 3V6, Canada.

ORCID-Profile: Christine Brezden-Masley, Nadia Califaretti, Jan-Willem Henning, Nathalie LeVasseur

Förderung

  • Eli Lilly (Canada)
  • Karamjeet Singh, PhD and Andrea Brumwell, PhD of MEDUCOM Health Inc.
  • Eli Lilly Canada Inc.

Zitieren

APA

Jerzak, K. J., Sehdev, S., Boileau, J. F., Brezden-Masley, C., Califaretti, N., Edwards, S., Gordon, J., Henning, J. W., LeVasseur, N., & Railton, C. (2025). Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada. Current Oncology. https://doi.org/10.3390/curroncol32080444

Vancouver

Jerzak KJ, Sehdev S, Boileau JF, Brezden-Masley C, Califaretti N, Edwards S, et al. Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada. Current Oncology. 2025. doi:10.3390/curroncol32080444

BibTeX
@article{Jerzak2025,
  author = {Jerzak, Katarzyna J and Sehdev, Sandeep and Boileau, Jean-François and Brezden-Masley, Christine and Califaretti, Nadia and Edwards, Scott and Gordon, Jenn and Henning, Jan-Willem and LeVasseur, Nathalie and Railton, Cindy},
  title = {Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32080444}
}
Kostenlos starten →